April 17 (Reuters) - Eli Lilly's ( LLY ) weight-loss
drug succeeded in two late-stage trials testing it in patients
with obstructive sleep apnea, the company said on Wednesday.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Sriraj
Kalluvila)